HISTOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.351 USD | +0.26% |
|
+133.84% | +14.07% |
| 04-19 | Subchapter V Trustee Appointed Under Chapter 11 for Histogen Inc. | CI |
| 04-18 | Histogen Inc. Filed for Bankruptcy | CI |
| Sales 2021 | 1.03M 82.45M | Sales 2022 | 3.77M 301M | Capitalization | 3.55M 283M |
|---|---|---|---|---|---|
| Net income 2021 | -15M -1.2B | Net income 2022 | -10M -799M | EV / Sales 2021 | 2.62 x |
| Net cash position 2021 | 13.92M 1.11B | Net cash position 2022 | 7.48M 597M | EV / Sales 2022 | -1.04 x |
| P/E ratio 2021 |
-0.85
x | P/E ratio 2022 |
-0.24
x | Employees | 7 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.15% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.26% | ||
| 1 week | +133.84% | ||
| Current month | -2.53% | ||
| 1 month | -2.53% | ||
| 3 months | -5.14% | ||
| 6 months | +9.48% | ||
| Current year | +14.07% |
1 week
0.35
0.40
1 month
0.050.55
Current year
0.050.55
1 year
0.051.05
3 years
0.0524.60
5 years
0.05105.24
10 years
0.05105.24
| Managers | Title | Age | Since |
|---|---|---|---|
Susan Knudson
CEO | Chief Executive Officer | 60 | 26/05/20 |
Mark A. Hubka
CTO | Chief Tech/Sci/R&D Officer | - | - |
Thomas L. Hubka
PRN | Corporate Officer/Principal | 37 | 25/05/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Kisner
CHM | Chairman | 77 | 31/01/14 |
| Director/Board Member | 54 | 24/03/21 | |
David Crean
BRD | Director/Board Member | 59 | 25/05/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.351 | +0.26% | 1,034 |
| 24/04/24 | 0.3501 | +0.03% | 6,956 |
| 22/04/24 | 0.35 | +133.18% | 55,183 |
Delayed Quote OTC Markets, April 26, 2024 at 02:30 pm
More quotes
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the bodyâs natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +14.07% | 1.5M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- HSTO Stock
